Silk Road Medical Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	177.13	138.64	101.48	75.23	63.35	34.56	14.26
Revenue Growth (YoY)	27.77%	36.62%	34.89%	18.74%	83.33%	142.37%	-
Cost of Revenue	50.05	37.88	25.45	21.29	15.93	10.87	5.13
Gross Profit	127.09	100.76	76.03	53.94	47.43	23.68	9.13
Selling, General & Admin	145.03	116.32	96.39	75.52	63.22	34.82	20.26
Research & Development	41.32	36.45	27.11	21.27	12.27	10.26	7.24
Operating Expenses	186.36	152.77	123.5	96.8	75.49	45.08	27.5
Operating Income	-59.27	-52	-47.47	-42.86	-28.07	-21.4	-18.37
Interest Expense / Income	6.87	5.1	2.52	4.41	4.95	4.36	3.94
Other Expense / Income	-10.4	-2.09	-0.18	0.06	19.4	11.87	-2.96
Pretax Income	-55.74	-55.01	-49.81	-47.33	-52.41	-37.63	-19.36
Net Income	-55.74	-55.01	-49.81	-47.33	-52.41	-37.63	-19.36
Shares Outstanding (Basic)	39	36	35	33	23	1	0
Shares Outstanding (Diluted)	39	36	35	33	23	1	0
Shares Change	8.47%	3.29%	5.07%	43.60%	2289.13%	121.32%	-
EPS (Basic)	-1.44	-1.54	-1.44	-1.44	-2.28	-39.16	-44.58
EPS (Diluted)	-1.44	-1.54	-1.44	-1.44	-2.28	-39.16	-44.58
Free Cash Flow	-33.52	-37.59	-43.69	-42.91	-30.15	-23.97	-25.7
Free Cash Flow Per Share	-0.86	-1.05	-1.26	-1.30	-1.31	-24.94	-59.18
Gross Margin	71.75%	72.68%	74.92%	71.70%	74.86%	68.53%	64.03%
Operating Margin	-33.46%	-37.51%	-46.78%	-56.97%	-44.30%	-61.91%	-128.87%
Profit Margin	-31.47%	-39.68%	-49.09%	-62.91%	-82.73%	-108.89%	-135.76%
Free Cash Flow Margin	-18.92%	-27.11%	-43.06%	-57.04%	-47.58%	-69.35%	-180.21%
EBITDA	-45.08	-46.74	-45.37	-41.53	-46.17	-32.75	-15.28
EBITDA Margin	-25.45%	-33.72%	-44.71%	-55.20%	-72.87%	-94.77%	-107.20%
Depreciation & Amortization	3.79	3.17	1.92	1.39	1.29	0.52	0.13
EBIT	-48.87	-49.91	-47.29	-42.92	-47.46	-33.27	-15.41
EBIT Margin	-27.59%	-36.00%	-46.61%	-57.05%	-74.91%	-96.27%	-108.10%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).